酷代码 AI
菜单
服务商

替雷利珠单抗是一种抗pd-1免疫检查点抑制剂,广泛应用于多种肿瘤的免疫治疗中,可能引发免疫相关性不良反应,罕见但严重的并发症之一为免疫相关性糖尿病。该类型糖尿病通常呈现1型糖尿病的特征,发病迅速且不可逆,通常伴随糖尿病酮症酸中毒的急性发作。该文报道1例替雷利珠单抗注射液致免疫相关性糖尿病的病例,通过分析现有文献和临床案例,总结替雷利珠单抗引发免疫相关性糖尿病的临床特征,探讨免疫检查点抑制剂致糖尿病潜在的发病机制、处理、药学监护,以期在临床使用中警惕抗pd-1免疫检查点抑制剂引起的免疫相关不良反应。翻译成英文

Tislelizumab is an anti-PD-1 immune checkpoint inhibitor that is widely used in the immunotherapy of various tumors. It may cause immune-related adverse reactions. One of the rare but serious complications is immune-related diabetes. This type of diabetes usually presents the characteristics of type 1 diabetes, has a rapid and irreversible onset, and is often accompanied by acute episodes of diabetic ketoacidosis. This article reports a case of immune-related diabetes caused by tislelizumab injection. By analyzing existing literature and clinical cases, the clinical characteristics of immune-related diabetes caused by tislelizumab are summarized, and the potential pathogenesis, treatment, and pharmaceutical care of diabetes caused by immune checkpoint inhibitors are discussed, in order to be vigilant about the immune-related adverse reactions caused by anti-PD-1 immune checkpoint inhibitors in clinical use. [2024-10-11 14:52:52 | AI写代码神器 | 164点数解答]

相关提问
请收藏新域名:pdcd.cn
发财导航,免费问AI
实用工具查看更多
今日油价 [生活类]
图片互转base64 [开发类]
时间转换器 [开发类]
数独游戏 [娱乐类]
经典推箱子 [娱乐类]
AI摸鱼五子棋 [娱乐类]